Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
HOOKIPA Pharma Inc. is a clinical-stage biotechnology company focused on the development of immunotherapeutics based on its proprietary arenavirus platform. The company operates within the biotechnology and biopharmaceutical industries, with primary emphasis on oncology and infectious diseases. Its core strategy centers on leveraging engineered arenaviruses to stimulate robust immune responses, particularly cytotoxic T-cell activity, against cancer targets and chronic viral infections.
The company’s primary value drivers are its pipeline of therapeutic candidates and its underlying technology platform, which is designed to enable repeat administration and strong antigen-specific immunity. HOOKIPA primarily serves pharmaceutical partners, healthcare systems, and ultimately patients through clinical development and potential out-licensing. Founded in 2011 and originally headquartered in Vienna, Austria, the company later expanded to the United States and completed an initial public offering on Nasdaq in 2019, reflecting its evolution from a research-focused startup to a publicly traded clinical-stage biotechnology company.
Business Operations
HOOKIPA conducts its operations through a single reportable segment focused on research and development, with activities spanning discovery, preclinical research, and clinical trials. Revenue generation has historically been driven by collaboration agreements, upfront payments, and research funding from strategic partners rather than product sales. The company does not currently have any commercialized products, and its financial performance is primarily influenced by R&D expenditures and partnership-related income.
Operationally, HOOKIPA controls its proprietary arenavirus-based vector technology and associated intellectual property. Its primary subsidiary, HOOKIPA Biotech GmbH, supports European research and development activities. The company has historically entered into strategic collaborations with large pharmaceutical companies for the development of oncology and infectious disease programs; however, the status and scope of certain partnerships have changed over time, and some programs have been discontinued. Where partnership continuity or program status is unclear, data is inconclusive based on available public sources.
Strategic Position & Investments
HOOKIPA’s strategic direction has emphasized pipeline prioritization, capital preservation, and selective advancement of clinical assets following a period of restructuring. Growth initiatives have included focusing resources on lead oncology programs and evaluating strategic alternatives for non-core assets. The company has also pursued cost-reduction measures to extend its operating runway, as disclosed in recent SEC filings.
Historically, HOOKIPA entered into major collaborations with global pharmaceutical companies, including agreements related to oncology and hepatitis B virus programs. Some of these collaborations have been restructured or terminated, reflecting shifting strategic priorities by both HOOKIPA and its partners. The company remains positioned within emerging immunotherapy technologies, particularly T-cell–focused viral vector approaches, though the long-term commercial viability of these assets remains subject to clinical outcomes and funding availability.
Geographic Footprint
HOOKIPA maintains a transatlantic operational footprint with headquarters in the United States and significant research operations in Europe, particularly Austria. Its U.S. presence supports corporate management, regulatory engagement, and investor relations, while European operations have historically anchored core scientific research and early development activities.
The company’s clinical and collaborative activities have extended its influence into additional regions, including North America and parts of Western Europe, primarily through multinational clinical trials and partnerships. HOOKIPA does not currently report material commercial operations in Asia, Latin America, or Africa, though its technologies are intended for global therapeutic applications.
Leadership & Governance
HOOKIPA is governed by a board of directors with experience in biotechnology, pharmaceuticals, and public company oversight. Leadership has emphasized scientific rigor, disciplined capital allocation, and strategic flexibility in response to evolving clinical and financial conditions. The company’s governance framework aligns with U.S. public company standards and is detailed in its SEC filings.
Key executives reported in recent public disclosures include:
- Garrett M. Gross – President and Chief Executive Officer
- Stefan Lorenz – Chief Financial Officer
- Joern Aldag – Co-Founder and former Chief Executive Officer
- Raffael Schwickert – Chief Scientific Officer
Certain executive roles and responsibilities have evolved over time, and where discrepancies exist across reporting periods, data is inconclusive based on available public sources.